Literature DB >> 1429559

The lymphoma transmembrane glycoprotein GP85 (CD44) is a novel guanine nucleotide-binding protein which regulates GP85 (CD44)-ankyrin interaction.

V B Lokeshwar1, L Y Bourguignon.   

Abstract

In this study, we have used photoaffinity labeling by [32P]azido-GTP as well as [32P]ADP-ribosylation by pertussis toxin (PT) and cholera toxin (CT) to identify GTP-binding proteins associated with mouse T-lymphoma plasma membranes. Our results indicate that GP85 (CD44) can be photoaffinity labeled by [32P] azido-GTP and [32P]ADP-ribosylated by both PT and CT. Using purified GP85 (CD44) obtained by Triton X-100 extraction, wheat germ agglutinin-Sepharose, and anti-GP85 (CD44) antibody affinity chromatographies, we have further characterized GP85 (CD44) as a GTP-binding protein. GP85 (CD44) is found to bind guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) in a time- and dose-dependent manner with a dissociation constant of 0.83 nM. Importantly, GP85 (CD44) appears to display a GTPase activity which hydrolyzes [gamma-32P]GTP at a rate of 0.011 mol of Pi released/mol of GP85 (CD44)/min. This GTPase activity can be readily inhibited by PT- or CT-mediated ribosylation of GP85 (CD44). Most interestingly, GTP binding significantly enhances the interaction of purified GP85 (CD44) with ankyrin, whereas ADP-ribosylation of GP85 (CD44) by PT or CT inhibits the GTP-induced increase in ankyrin binding to GP85 (CD44). In addition to GP85 (CD44) being the first reported transmembrane GTP-binding protein, these results suggest that GTP plays an important role in promoting the interaction between GP85 (CD44) and its underlying membrane cytoskeleton through ankyrin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1429559

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix.

Authors:  C A Henke; U Roongta; D J Mickelson; J R Knutson; J B McCarthy
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 2.  CD44 and the adhesion of neoplastic cells.

Authors:  Z Rudzki; S Jothy
Journal:  Mol Pathol       Date:  1997-04

3.  Expression of CD44 variants in human inflammatory synovitis.

Authors:  L P Hale; B F Haynes; S S McCachren
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

4.  Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells.

Authors:  Sai P Thankamony; Robert Sackstein
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-21       Impact factor: 11.205

Review 5.  Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis.

Authors:  L Y Bourrguignon; N Iida; C F Welsh; D Zhu; A Krongrad; D Pasquale
Journal:  J Neurooncol       Date:  1995-12       Impact factor: 4.130

Review 6.  Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis.

Authors:  C L Hall; E A Turley
Journal:  J Neurooncol       Date:  1995-12       Impact factor: 4.130

Review 7.  Glycosyltransferase-programmed stereosubstitution (GPS) to create HCELL: engineering a roadmap for cell migration.

Authors:  Robert Sackstein
Journal:  Immunol Rev       Date:  2009-07       Impact factor: 12.988

8.  Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation.

Authors:  R W Hurley; J B McCarthy; C M Verfaillie
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 9.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

10.  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Authors:  Kui Yang; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.